Back to top
more

Teva Pharmaceutical Industries (TEVA)

(Delayed Data from NYSE)

$18.45 USD

18.45
7,100,133

+0.01 (0.05%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $18.45 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 20% (49 out of 250)

Industry: Medical - Generic Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Kevin Cook headshot

Bear of the Day: Mallinckrodt PLC (MNK)

by Kevin Cook

Generic drug makers are one of the worst performing industries this year and there's little sign of a turnaround

    Teva's New CEO Re-Shuffles Senior Management, Stock Up 7%

    by Zacks Equity Research

    Teva (TEVA) announced several organizational changes in order to save costs and improve productivity.

      Teva (TEVA) Stock Rises 5% on Reports of Massive Job Cuts

      by Zacks Equity Research

      Per an Israeli news release, Teva (TEVA) is expected to lay off 4000 employees

        AstraZeneca's (AZN) Asthma Drug Benralizumab Approved by FDA

        by Zacks Equity Research

        AstraZeneca (AZN) received FDA approval for benralizumab for treating severe eosinophilic asthma.

          Orexigen (OREX) Q3 Loss Narrower Than Expected, Stock Up

          by Zacks Equity Research

          Orexigen (OREX) reported a narrower-than-expected loss on higher Contrave volumes.

            BioDelivery (BDSI) Q3 Earnings, Sales Beat Estimates

            by Zacks Equity Research

            BioDelivery (BDSI) reports narrower-than-expected loss in Q3. Revenues also surpass estimates and increase significantly year over year.

              VIVUS (VVUS) Q3 Loss Narrows, Qsymia Falters, Shares Down

              by Zacks Equity Research

              VIVUS (VVUS) reported third-quarter results wherein it reported narrower-than- expected loss. However, Qsymia sales fell from the year-ago period.

                Mylan (MYL) Misses on Earnings and Sales Estimates in Q3

                by Zacks Equity Research

                Mylan (MYL) missed both earnings and sales estimates in the third quarter of 2017 as EpiPen sales continue to decline further.

                  Teva (TEVA) Stock Plunges 20% on Q3 Earnings Miss & View Cut

                  by Zacks Equity Research

                  Teva's (TEVA) third-quarter earnings missed estimates while revenues were in line. The company lowered its earnings and revenue guidance for 2017, for the second time this year.

                    Momenta's (MNTA) Biosimilar Study Fails, Q3 Loss Narrows

                    by Zacks Equity Research

                    Momenta Pharmaceuticals (MNTA) study to evaluate a biosimilar version of Orencia failed which overshadowed the third-quarter results.

                      Teva (TEVA) Q3 Earnings Miss, Cuts 2017 View, Stock Falls

                      by Zacks Equity Research

                      Teva (TEVA) third quarter earnings missed estimates while revenues were in line. The company lowered its earnings and revenue guidance for 2017, for the second time this year.

                        Allergan (AGN) Tops Q3 Earnings Estimates, Tweaks 2017 View

                        by Zacks Equity Research

                        Allergan (AGN) beat expectations for earnings while delivering in-line revenues in Q3. While the company slightly lowered its sales guidance, it raised the upper end of the earnings guidance.

                          Is a Turnaround in Store for Teva (TEVA) in Q3 Earnings?

                          by Zacks Equity Research

                          Teva's (TEVA) generic segment may continue to see weakness due to significant competitive and pricing pressure in the U.S. generics industry, which will continue to hurt the top line.

                            Teva Submits BLA to FDA for Migraine Candidate Fremanezumab

                            by Zacks Equity Research

                            Teva Pharma (TEVA) submits BLA seeking approval for its pipeline candidate, Fremanezumab, as a preventive treatment for migraine in the United States.

                              Zacks Market Edge Highlights: Gilead, Biogen, Teva, AbbVie and Aetna

                              by Zacks Equity Research

                              Zacks Market Edge Highlights: Gilead, Biogen, Teva, AbbVie and Aetna

                                Arpita Dutt headshot

                                Pricing Pressure, Competition Remain Headwinds for Pharma Stocks

                                by Arpita Dutt

                                Although the pharma and biotech sectors have rebounded in 2017, drug companies may find it a bit difficult to justify their high prices.

                                  Tracey Ryniec headshot

                                  Where to Find Value in Healthcare Stocks

                                  by Tracey Ryniec

                                  The Biotech stocks have been on a big run in 2017, but that doesn't mean there aren't some healthcare values still out there.

                                    Allergan (AGN) Loses Restasis Patent Lawsuit, Shares Fall

                                    by Zacks Equity Research

                                    Allergan (AGN) lost a patent infringement lawsuit filed against companies trying to develop a generic version of its eye drug, Restasis, which is also its second bestselling drug.

                                      Zacks Industry Outlook Highlights: Gilead, Teva, Pfizer and Amgen

                                      by Zacks Equity Research

                                      Zacks Industry Outlook Highlights: Gilead, Teva, Pfizer and Amgen

                                        Arpita Dutt headshot

                                        Pharma Industry Outlook - October 2017

                                        by Arpita Dutt

                                        New product sales ramping up, R&D success and innovation, strong results, a higher number of FDA approvals and continued strong performance from key products are some of the factors that could contribute to a sustained recovery in the sector.

                                          Mylan Gets Complete Response Letter For Biosimilar Neulasta

                                          by Zacks Equity Research

                                          Mylan (MYL) suffered a setback following the FDA's CRL for the company's BLA for MYL-1401H, a proposed biosimilar of Neulasta.

                                            Lilly Wins Favorable Ruling From U.S. PTO in Alimta Dispute

                                            by Zacks Equity Research

                                            Lilly (LLY) has received a favorable ruling from the U.S. PTO in a dispute related to vitamin regimen patent on its key cancer drug, Alimta.

                                              Teva Down as Mylan's Copaxone 40 mg Generic Arrives Early

                                              by Zacks Equity Research

                                              Teva's (TEVA) shares plunged after Mylan announced an earlier-than-expected launch of its generic version of the 40-mg thrice-weekly formulation of its blockbuster multiple sclerosis drug, Copaxone.

                                                Ryan McQueeney headshot

                                                Teva Shares Plummet After Mylan's Copaxone Generic Gets FDA Approval

                                                by Ryan McQueeney

                                                Shares of Teva Pharmaceuticals (TEVA) opened more than 13% lower on Wednesday, plunging close to their 52-week low in the process. The struggling Israeli pharma firm, which has faced significant pressure to reduce its debt load, is sliding once again--this time because of a brand new competitor.

                                                  Mylan (MYL) Gets FDA Approval for Generic Copaxone 40mg

                                                  by Zacks Equity Research

                                                  Mylan N.V. (MYL) gets a boost with the FDA's approval of the generic version of multiple sclerosis drug Copaxone.